Top 10 Books about Stock Investing to read in 2018. Read more.

CBIO - Catalyst Biosciences

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ

CBIO - Catalyst Biosciences

Industry: Biotechnology Sector: Healthcare Exchange: NASDAQ
#1552()/6683

Fri 23'rd Mar 2018

PERIOD 2017-12-26 - 2018-03-23
CHANGE -0.94%
PRICE $27.51
VOLUME
Sell
TREND
Buy

MV LONG
Sell

MV SHORT
Sell

PIVOT
Sell

MACD
Buy

0.00%

Catalyst Biosciences Stock Analysis

Technical stock analysis for Fri 23'rd Mar 2018

Hold candidate since 2018-03-22 Loss -0.94%

Catalyst Biosciences fell by -0.94% in the last day from $27.77 to $27.51 and has now fallen 4 days in a row. The price has fallen in 5 of the last 10 days and is down by -1.86% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -2 775 shares and in total 120 458 shares bought and sold for approximately $3.31 million.

Shorts 0.25% ( 2018-02-28 )
Cash 74.4 mill
Loans n/a
Beta 2.12
ROA -61.50

Trend

Catalyst Biosciences lies in the lower part of a very wide and strong rising trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at $27.45 will firstly indicate a slower raising rate, but may also be a early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 63.75% during the next 3 months and, with 90% probability hold a price between $44.94 and $71.24 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

There are few to none technical positive signals at the moment. Catalyst Biosciences holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $28.04 and $28.51. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Tuesday March 20, 2018, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

The stock currently holds a RSI14 at 26 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Access full RSI 14 and RSI 21 lists

Support & Resistance

Catalyst Biosciences finds support from accumulated volume at $27.20. On the upside the stock meets some resistance just above today's level from accumulated volume at $27.54, $32.40 and $34.36.

The stock is about to test the resistance from accumulated volume at $27.54 and this may cause the stock to take a minor break or get into a more sideways move for a few days.

Support: $27.20 Price: $27.51 Resistance: $27.54

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.22 between high and low, or 4.45%. For the last week, the stock has had a daily average volatility of 5.60%.

Catalyst Biosciences is oversold on RSI14 (26). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stoploss: $25.73 (-6.48%) (This stock has medium daily movements and this gives medium risk. Low RSI14 is 26 which reduces the risk some. There is a sell signal from pivot top found 3 days ago.)

Overall risk:

Very Low Low Medium High Very High

Trade CBIO CFDs with Plus500

Your capital is at risk.

Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).

START FREE 5-DAY TRIAL